Lidocaine per-embolization — Competitive Intelligence Brief

Lidocaine per-embolization (Lidocaine per-embolization) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Interventional Radiology / Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Interventional Radiology / Pain Management Small molecule

Target snapshot

Lidocaine per-embolization (Lidocaine per-embolization) — University Health Network, Toronto. Lidocaine is a local anesthetic administered before embolization procedures to reduce pain and discomfort during the interventional radiological intervention.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine per-embolization TARGET	Lidocaine per-embolization	University Health Network, Toronto	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine liposomal injectable suspension	Bupivacaine liposomal injectable suspension	The University of Texas Health Science Center, Houston	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Anesthesia (Lidocaine 15%)	Anesthesia (Lidocaine 15%)	Lumbini Medical College	marketed	Local anesthetic	Voltage-gated sodium channels
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Ropivacaine + dexamethasone	Ropivacaine + dexamethasone	Sahiwal medical college sahiwal	marketed	Local anesthetic with corticosteroid adjuvant	Voltage-gated sodium channels; glucocorticoid receptor
Bupivacaine standard dose	Bupivacaine standard dose	Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias	marketed	Local anesthetic (amide)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class